By Dan Baker, MD, VP, Immunology Therapeutic Area, Janssen Research & Development, LLC
Today is World Psoriasis Day, an important date established to raise the profile and reduce the stigma that surrounds psoriasis. This day is truly global in its reach -- created by, and dedicated to, the 125 million people living with psoriasis and psoriatic arthritis around the world.
Psoriasis is characterized by red, scaly and often itchy patches on the skin. Symptoms can range from mild -- a few patches in select areas -- to severe, with plaques covering more than 10 percent of the body.
Psoriasis is the most common immune-mediated skin disorder in the world, affecting nearly three percent of the world’s population. But despite the disease’s widespread impact, psoriasis is often misunderstood, and people affected sometimes face public humiliation as a result of their symptoms. Though it is often characterized as a ‘skin condition,’ psoriasis is much more than that – it is an inflammatory disease resulting in increased risk of other severe conditions and even increased morbidity.
That’s why at Janssen, we are committed to making a difference in the lives of people living with psoriasis through ongoing research and bringing forward new treatment options. The Janssen pharmaceutical companies continue to be a leader focused in this disease area, and while I am proud of our accomplishments to date, I am excited about the future as our work continues.
We’re working hard to develop effective and innovative new treatments to help patients at all stages of this disease. Today, as we recognize World Psoriasis Day, the future is bright for those living with this disease. Thanks to innovation, science and our dedicated team -- we continue to fulfill our commitment to improve the lives of people battling the devastating effects of a disease like psoriasis.